{
    "2021-08-16": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Eli Lilly Stock Soars To 96 Composite Rating",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Stock Soars",
                        "Composite Rating"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-02",
                "original_text": "Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer",
                "features": {
                    "keywords": [
                        "Innovent",
                        "Sintilimab",
                        "Overall Survival Benefit",
                        "Gastric Cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-03",
                "original_text": "Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Lebrikizumab",
                        "Clinical Benefit",
                        "Atopic Eczema",
                        "Trials"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "dermatology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-04",
                "original_text": "FDA Approves LyumjevÂ® (insulin lispro-aabc injection) 100 units/mL for Use in Insulin Pumps",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "Lyumjev",
                        "Insulin Pumps"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diabetes care"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials",
                "features": {
                    "keywords": [
                        "Lilly",
                        "lebrikizumab",
                        "skin clearance",
                        "itch",
                        "atopic dermatitis",
                        "Phase 3 trials"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "dermatology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}